WORK Medical Technology Group LTD
WOKHealthcareNASDAQMedical Devices · Last scanned Oct 23, 2026
Scan Results
Daily timeframePart of the healthcare sector, WORK Medical Technology Group LTD (WOK) is listed under Medical Devices. Valued at $5.0M, WOK is a micro-cap name in its sector. The company offers medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, yankauer suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half masks; visualized prostatic dilatation catheters; and nebulizer kits, SPO2 sensors, nasogastric tubes, personal protective equipment, hygiene and skincare products, cleaners for household use, and non-powered air-purifying particle respirators.
Market Cap
$5.0M
Beta
1.74
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-51993.25
EPS (Fwd)
—
ROE
-19.2%
ROA
-6.7%
Cash
$3.3M
Total Debt
$6.6M
Free CF
-$2.2M
52W Change
-100.0%
Annual Financials
Cash vs Debt
Where WOK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, WOK finished 97.23% below its 150-day moving average ($43.39) and 98.36% below its 200-day moving average ($73.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WOK overbought or oversold?
At the October 20, 2026 close, WOK's RSI(14) was 20.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $3.3M in cash, though total debt stands at $6.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$2.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -19.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $19.7M (2022) to $9.8M (2025), a 50% decline worth watching.
WORK Medical Technology Group LTD's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence WORK Medical Technology Group LTD's trajectory.